Ibrutinib in PCNSL: The curious cases of clinical responses and aspergillosis Journal Article

   

Authors:	Grommes, C.; Younes, A.
Article Title:	Ibrutinib in PCNSL: The curious cases of clinical responses and aspergillosis
Abstract:	In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was associated with significant toxicity, including pulmonary and cerebral aspergillosis infections. © 2017
Journal Title:	Cancer Cell
Volume:	31
Issue:	6
ISSN:	1535-6108
Publisher:	Cell Press
Date Published:	2017-06-12
Start Page:	731
End Page:	733
Language:	English
DOI:	10.1016/j.ccell.2017.05.004
PROVIDER:	scopus
PUBMED:	28552326
PMCID:	PMC5572136
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019918895&doi=10.1016%2fj.ccell.2017.05.004&partnerID=40&md5=e069418e61a6a1c53e1f5c41728fbe5e
Notes:	Short Survey -- Export Date: 3 July 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/112435